During the past decade, Green Bay Oncology - Escanaba conducted 52 clinical trials. In the 10-year time frame, 52 clinical trials started and 93 clinical trials were completed, i.e. on average, 178.8% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 48 clinical trials were completed. i.e. 685.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Green Bay Oncology - Escanaba" #1 sponsor was "National Cancer Institute (NCI)" with 84 trials, followed by "SWOG Cancer Research Network" with 22 trials sponsored, "Alliance for Clinical Trials in Oncology" with 13 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 6 trials sponsored and "Gynecologic Oncology Group" with 6 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Green Bay Oncology - Escanaba" #1 collaborator was "National Cancer Institute (NCI)" with 58 trials as a collaborator, "NRG Oncology" with 17 trials as a collaborator, "NCIC Clinical Trials Group" with 7 trials as a collaborator, "Cancer and Leukemia Group B" with 6 trials as a collaborator and "SWOG Cancer Research Network" with 6 trials as a collaborator. Other collaborators include 31 different institutions and companies that were collaborators in the rest 26 trials.

According to Clinical.Site data, the most researched conditions in "Green Bay Oncology - Escanaba" are "Recurrent Breast Carcinoma" (12 trials), "Recurrent Squamous Cell Lung Carcinoma" (8 trials), "Stage IV Breast Cancer AJCC v6 and v7" (8 trials), "Recurrent Ovarian Carcinoma" (7 trials) and "Fallopian Tube Transitional Cell Carcinoma" (6 trials). Many other conditions were trialed in "Green Bay Oncology - Escanaba" in a lesser frequency.

Most popular intervention types in "Green Bay Oncology - Escanaba" are "Drug" (122 trials), "Other" (104 trials), "Biological" (64 trials), "Procedure" (22 trials) and "Radiation" (10 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (71 trials), "Quality-of-Life Assessment" (39 trials), "Paclitaxel" (23 trials), "Carboplatin" (22 trials) and "Bevacizumab" (20 trials). Other intervention names were less common.

The vast majority of trials in "Green Bay Oncology - Escanaba" are 106 trials for "All" genders, 31 trials for "Female" genders and 5 trials for "Male" genders.

Currently, there are NaN active trials in "Green Bay Oncology - Escanaba". undefined are not yet recruiting, 9 are recruiting, 73 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 52 completed trials in Green Bay Oncology - Escanaba, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Green Bay Oncology - Escanaba, 5 "Phase 1" clinical trials were conducted, 56 "Phase 2" clinical trials and 85 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".